Tedalinab (GRC-10693) is a drug developed by
Glenmark Pharmaceuticals for the treatment of
osteoarthritis and
neuropathic pain, which acts as a potent and selective
cannabinoid CB2 receptor
Receptor may refer to:
* Sensory receptor, in physiology, any structure which, on receiving environmental stimuli, produces an informative nerve impulse
*Receptor (biochemistry), in biochemistry, a protein molecule that receives and responds to a ...
agonist
An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...
. It has a very high selectivity of 4700x for CB
2 over the related
CB1 receptor, has good oral bioavailability and has shown promising safety results and effective
analgesic
An analgesic drug, also called simply an analgesic (American English), analgaesic (British English), pain reliever, or painkiller, is any member of the group of drugs used to achieve relief from pain (that is, analgesia or pain management). It ...
and
antiinflammatory actions in early
clinical trials. Many related compounds are known, most of which also show high CB
2 selectivity.
Glenmark Pharmaceuticals. NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION, Filed June 1st, 2006. WO 2006/129178.
/ref>
See also
* CBS-0550
* Olorinab
Olorinab (APD371) is a drug being drug development, developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome. It acts as a potent and selective cannabinoid Cannabin ...
* SER-601
References
Cannabinoids
Tert-butyl compounds
Fluoroarenes
Nitrogen heterocycles
{{cannabinoid-stub